Contents
Contents
In drug pricing, reasonable assumptions shape the reported number, and a restatement revises it. What matters is what changed in the calculation, when it changed and what the company knew. A manufacturer chooses which transactions belong in a government price, certifies the result and may later revise it. If you work in government pricing, the important document may be the calculation before the internal review, beside the one management approved afterward. Between them sits a decision that can change what Medicaid receives in rebates or what Medicare pays for a drug.
Average manufacturer price, Best Price and average sales price measure different transactions and serve different programs. The purchaser, the concession and the reporting period determine where a payment belongs.
Average manufacturer price, usually called AMP, generally measures prices paid to the manufacturer by wholesalers for drugs distributed to retail community pharmacies and by those pharmacies buying directly. Best Price is the lowest qualifying manufacturer price, with specified exclusions. Both feed Medicaid rebate calculations. A lower AMP or a higher Best Price generally reduces the manufacturer’s rebate obligation, leaving taxpayers with more of Medicaid’s drug bill. An additional rebate applies when AMP rises faster than inflation, so the historical price baseline matters too.
Those inputs also reach safety-net healthcare providers. The 340B ceiling price uses AMP minus the Medicaid rebate amount. A decision made in a manufacturer’s pricing department can therefore change both a state’s rebate and the price a covered provider pays for drugs used in patient care.
Average sales price, or ASP, feeds Medicare Part B drug payments. It uses manufacturer sales and units across a broader set of purchasers, with its own exclusions and treatment of discounts, rebates and chargebacks. The same payment needs to be examined against the benchmark the company actually reported.
The industry’s public prices offer only part of this picture. The Association Between Drug Rebates and List Prices, a 2020 USC Schaeffer Center white paper, found that higher estimated rebates were associated with higher list prices. The analyst inside the company can trace the contracts and payments behind its reported prices.
A reasonable assumption fills a gap in how a manufacturer applies government pricing requirements to its transactions. It must fit the law and regulations, and the manufacturer must document its basis.
In its September 2019 report on reasonable assumptions, the Department of Health and Human Services Office of Inspector General found that 91 of 103 responding manufacturers used assumptions in at least one area. Their decisions included how to treat service fees, bundled sales and discounts arriving after the sale.
A bona fide service fee turns on fair market value, an itemized service actually performed for the manufacturer, work the manufacturer would otherwise perform or buy, and whether the recipient passes the fee to a customer. The assumption file can show how the company decided those facts. A revised conclusion about a wholesaler’s fee can move the reported price even when the underlying payment stays the same.
Product information matters alongside the money. A drug’s strength, dosage form, unit type and market date help identify the calculation and its baseline. The Centers for Medicare & Medicaid Services’ 2024 Medicaid rule ties the market date for new products to the first sale by any manufacturer. Buying a drug from another company does not restart its pricing history.
Pharmaceutical rebate and chargeback reconciliation follows payments that can arrive after the sale they adjust. The contract, transaction and certified price report can therefore tell different parts of the same story.
Value-based purchasing makes the timing especially visible. A contract can tie payment to a clinical outcome measured after the drug was sold. The Office of Inspector General recorded manufacturers’ concerns about sales in one reporting quarter followed by an effectiveness assessment and a price-adjusting discount in another.
Indication-Specific Drug Pricing–Simple in Theory, Complex in Reality, published in Managed Care in 2018, describes a related arrangement: the parties begin with a price weighted by expected uses, then reconcile actual use through rebates. The article identifies a practical obstacle. The condition being treated may appear in the medical record without being captured when the drug is dispensed.
For a pricing review, that makes the contract’s measure, the source of the outcome or use data, and the later reconciliation part of the same story. A spreadsheet showing only the final discount leaves out why that discount arose and which sales it adjusted.
The audit trail connects the original transaction to the reported price and then to the decision to change it. We examine it in the order the business made those decisions.
We trace the drug, purchaser and reporting quarter through the contract and payment records. Then we compare how the calculation treated the concession or service fee with the explanation in the assumption file.
The next comparison is between versions. What did the original calculation include? What did the reviewer change? Did new transaction data arrive, did a formula change, or did management choose a different interpretation? The dated explanation and the person responsible for approving it give the revised number its context.
Certification connects that work to the government report. Medicaid price reports require certification by the chief executive, chief financial officer, someone with equivalent authority or a directly delegated individual. We connect the approved calculation to the version certified and the information available to the signer.
The Centers for Medicare & Medicaid Services’ final rule also explains why an unfinished correction matters. In the ordinary product-data correction process, an entered change awaits certification before it becomes final for quarterly rebate calculations. Previously certified values remain in effect while the change sits uncertified. An internal review, an edited field and a completed correction are separate events in the file.
For a late AMP restatement, reasonable assumptions documentation needs to explain the original treatment and what the later review found. The ordinary Medicaid revision window is 12 quarters from the quarter in which the data were due, or three years. The Centers for Medicare & Medicaid Services’ 2024 final rule, effective November 19, 2024, explains the internal-investigation exception for older revisions.
Under that exception, the manufacturer must find possible fraud, abuse or a violation of law or regulation, with data supporting the finding available to CMS. Calling a review an internal investigation supplies neither. Other grounds for older corrections include agency or court direction and government investigations.
A change of ownership or a preference for another compliant method does not reopen older pricing by itself. The agency explained why this matters: very old revisions can become demands for substantial rebates back from states. A manufacturer’s preferred calculation can take money back out of a health care program long after the drug was sold.
Manufacturers must retain pricing records for ten years, including their calculation assumptions. A known government pricing investigation or audit begun within that period can require keeping them longer. The earlier decision may therefore still be visible in the company’s own files.
The retention period does not erase unpaid rebates. In its discussion of drug misclassification, the agency says corrections reach back to the misclassification and the obligation to pay past-due rebates has no corresponding ten-year cutoff. Where older records are unavailable, it allows reasonable assumptions about the missing data. Reconstructing missing data and changing the treatment of known transactions are different decisions for us to examine.
The Office of Inspector General’s report described selective review of Medicaid pricing assumptions. The Centers for Medicare & Medicaid Services assessed them case by case, while instructing manufacturers to keep their assumption records themselves. The report put the gap plainly:
However, under current practices, CMS never assesses the majority of these assumptions.
Reasonable Assumptions in Manufacturer Reporting of AMPs and Best Prices, HHS-OIG, September 2019
Manufacturers certify the prices that determine what Medicaid gets back, yet the report found most of the assumptions behind those prices went unexamined. The agency’s instructions reproduced in the report said receipt of an unsolicited assumptions submission should not be treated as agreement. When a company says its method went to CMS, we look for the agency’s response about that method.
Oversight takes other forms, too. The Office of Inspector General’s 2014 audit of 20 selected manufacturers found their AMP methodologies generally consistent with federal requirements. Its separate 2019 review of Part B price substitutions used reported ASP and AMP figures without verifying the underlying data or calculation methods.
Medicare Part B now has a more specific documentation requirement. Under the Medicare Part B reporting rule, beginning January 1, 2026, quarterly ASP submissions must include reasonable assumptions and the methodology used to determine fair market value, plus a service-fee recipient’s certification that the fee was not passed to its customer. CMS’s ASP reporting resources include forms for the assumptions and fee certification. Those documents connect the manufacturer’s calculation to a statement from the party receiving the money.
For ASP restatements before the third quarter of 2018, the agency’s instructions call for a summary of changes with Addendum A and B. We compare that explanation with the revised calculation.
Bristol-Myers Squibb agreed to pay $75 million in 2021 over allegations that it understated AMP by improperly deducting wholesaler service fees and excluding value received under price-appreciation provisions. Those provisions concerned value returned to the manufacturer when a price increase raised the value of a wholesaler’s inventory. The alleged result was less money back to Medicaid because the calculation left out value the manufacturer received.
Wyeth and Pfizer agreed to a $784.6 million settlement in 2016 over allegations that Wyeth omitted bundled discounts on oral and intravenous Protonix from Best Price. The alleged omission left Medicaid without the benefit of the bundled discount. Mylan’s 2017 EpiPen settlement concerned a different input: allegedly reporting the drug as a generic and avoiding rebates owed under its proper classification.
Regeneron’s ASP case reaches the discount records behind Medicare reimbursement. In April 2024, the Justice Department alleged that omitted credit-card processing fee payments inflated Eylea’s reported ASP. The whistleblowers’ complaint identifies an internal spreadsheet:
The 2015 ASP Spreadsheet confirms that, by 2015, Regeneron was paying or planning to pay customers two rebates that were not reported as part of ASP.
That allegation makes the comparison concrete: the rebates inside the pricing file against the concessions included in the government number. An analyst may know where that difference first appeared and who reviewed it.
A False Claims Act pricing case connects a knowingly false report to government money paid out or rebates left unpaid. We examine the transaction, the applicable calculation, the certification and what the company knew about the difference. An internal finding, a rejected correction or a revised assumption can help explain that sequence.
For someone who raised a pricing issue internally, the response belongs beside the original calculation. Who accepted the finding, which quarters were addressed and what ultimately reached CMS are the decisions we work through with you. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
If you know which assumption changed, what an internal review found or why a correction stopped short of the certified report, speak with our whistleblower experts about the pricing decision. We work beside you to connect the transactions, the government’s loss and the decisions inside the company, and bring in pharmaceutical whistleblower lawyers who understand government price reporting. We stay with you through the case.